Yarrow Bioscience
yarrowbioscience.com
Financial Services
Biotechnology
Health Care
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Raymond Debbane Reports 675,000 Shares in Yarrow Bioscience (NASDAQ: YARW) Representing 7.2% Passive Stake
Read more
Report
Yarrow Bioscience Prices $150 Million Public Offering
Yarrow Bioscience has priced an underwritten public offering expected to generate approximately $150 million in gross proceeds as the clinical-stage biotechnology company funds development of its autoimmune thyroid disease pipeline.
Read more
Report
Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering
NEW HAVEN, Conn., September 11, 2026--Yarrow Bioscience, Inc. ("Yarrow" or the "Company") (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced the pricing of
Read more
Report
Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update
NEW HAVEN, Conn., August 13, 2026--Yarrow Bioscience reports second quarter 2026 financial results and provides a business update.
Read more
Report
Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update
Yarrow Bioscience, Inc., a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced financial results for the second quarter ended June 30, 2026 and provided business updates. The
Read more
Report